Genovate Biotechnology Co., Ltd. (TPEX:4130)

Market Cap	3.03B +31.7%
Revenue (ttm)	471.48M -6.2%
Net Income	-9.17M
EPS	-0.08
Shares Out	113.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.10 (0.37%)
Ex-Dividend Date	Aug 20, 2025

Volume	97,881
Open	25.85
Previous Close	25.85
Day's Range	25.70 - 26.80
52-Week Range	17.65 - 40.15
Beta	0.09
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About Genovate Biotechnology

Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medicine, as well as cosmetics. Genovate Biotechnology Co., Ltd. was founded in 1982 and is based in Hsinchu City, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1982
• Employees: 190
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4130

Financial Performance

In 2025, Genovate Biotechnology's revenue was 492.41 million, a decrease of -3.61% compared to the previous year's 510.86 million. Earnings were 11.68 million, a decrease of -54.54%.